Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC
Clinical trial NCT06726161 · RECRUITING
Trial details
- NCT number
- NCT06726161
- Sponsor
- RayzeBio, Inc.
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2025-09-05
- Primary completion
- 2030-06-01
- Enrollment
- 590
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.